GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Indrayani Biotech Ltd

Indrayani Biotech Completes Rights Issue Allotment of 83,64,036 Shares

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 07:48 PM IST  ·  BSE ID: cb723ea9-1d41-4140-942d-145477abe83f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company finalized distributing new shares to existing shareholders after their rights issue application.
🤖 AI Summary
  • Indrayani Biotech finalized allotment of 83,64,036 Rights Equity Shares.
  • 75,03,333 shares were fully paid at Rs. 15; 8,60,703 shares partly paid at Rs. 3.75.
  • Allotment completed following consultation with BSE Limited on November 2, 2026.
  • Paid-up equity share capital increased to Rs. 53,25,47,648.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Number of Rights Equity Shares Allotted
83,64,036
Fully Paid Shares at Rs. 15
75,03,333
Partly Paid Shares at Rs. 3.75
8,60,703
Previous Paid-up Equity Share Capital
Rs. 45,53,62,560
New Paid-up Equity Share Capital
Rs. 53,25,47,648
🏢 How This Affects the Company
📈
Business Impact
The completion of the rights issue enhances the company's equity base, providing capital for future initiatives. The specific use of funds is not detailed in this filing.
💰
Financial Impact
Paid-up equity share capital has increased from Rs. 45,53,62,560 to Rs. 53,25,47,648, comprising fully and partly paid-up shares.
⚠️
Risk Impact
The increase in partly paid-up shares introduces a future call on shareholders for the remaining payment, which introduces a call risk until fully paid.
👥 What This Means For Shareholders
✅
Action Required
Shareholders who applied for the rights issue and were allotted shares have no further immediate action required unless a call is made for the balance amount.
👤
Who Is Affected
Shareholders who participated in the rights issue and were allotted shares. 75,03,333 shares are fully paid, and 8,60,703 shares are partly paid at Rs. 3.75.
🔍
Management Signal
Management has successfully executed the rights issue allotment process, demonstrating commitment to capital expansion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Future calls on the partly paid shares.
Company's financial results for subsequent periods.
Utilization of funds raised from the rights issue.
MEDIUM RISK Presence of partly paid shares introduces future call risk and execution risk on fund deployment.
💡 Investor Takeaway
Indrayani Biotech has completed the allotment of 83,64,036 Rights Equity Shares, increasing its paid-up capital to Rs. 53,25,47,648, with a portion remaining partly paid.
⚖️ Strengths & Concerns

✅ Positives

  • Completed allotment of 83,64,036 Rights Equity Shares, advancing capital raise objective.
  • Total paid-up equity share capital increased to Rs. 53,25,47,648 post-allotment.

⚠️ Concerns

  • A portion of 8,60,703 shares remains partly paid, with future payment obligations.
  • The filing does not provide details on the utilized amount of the rights issue.
📅 Company Track Record
Indrayani Biotech had previously postponed its Rs. 49.90 crore partly paid rights issue in June 2026. Earlier filings in April 2026 approved offer documents and confirmed ISIN for rights entitlement.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was the outcome of Indrayani Biotech's Rights Issue Committee meeting on November 03, 2026?
The committee approved the Basis of Allotment for 83,64,036 Rights Equity Shares, including 75,03,333 fully paid and 8,60,703 partly paid shares.
How many shares were fully paid and partly paid in Indrayani Biotech's rights issue allotment?
Out of 83,64,036 shares allotted, 75,03,333 shares were fully paid at Rs. 15, and 8,60,703 shares were partly paid at Rs. 3.75.
What is the total paid-up equity share capital of Indrayani Biotech after the rights issue allotment?
The company's paid-up equity share capital has increased to Rs. 53,25,47,648, comprising 5,30,39,589 fully paid and 8,60,703 partly paid equity shares.
What was the issue price for Indrayani Biotech's rights equity shares?
The issue price was Rs. 15 per Equity Share, including a premium of Rs. 5. For partly paid shares, Rs. 3.75 was paid on application, including a premium of Rs. 1.25.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.